Latest Hotspot

European Commission Approves Pierre Fabre's BRAFTOVI® and MEKTOVI® Combo for Advanced BRAFV600E-Mutant NSCLC Treatment

4 September 2024
3 min read

Pierre Fabre Laboratories has announced that the European Commission (EC) has granted approval for the use of BRAFTOVI® (encorafenib) in conjunction with MEKTOVI® (binimetinib) for adult patients suffering from advanced non-small cell lung cancer (NSCLC) harboring a BRAFV600E mutation. This decision follows data from the Phase II PHAROS trial, an international, open-label, multicenter, non-randomized study designed to assess the efficacy and safety of the BRAFTOVI® and MEKTOVI® combination in both treatment-naïve and previously treated patients with BRAFV600E mutant metastatic NSCLC.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Pierre Fabre Laboratories has gained European Commission approval for BRAFTOVI® (encorafenib) in conjunction with MEKTOVI® (binimetinib) for treating adult patients with advanced non-small cell lung cancer (NSCLC) harboring a BRAFV600E mutation.

Eric Ducournau, CEO of Pierre Fabre Laboratories, commented, "We are excited to expand the use of BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) to adult patients in Europe who have advanced NSCLC with a BRAFV600E mutation. Given the limited targeted treatment options available for BRAFV600E mutant NSCLC patients, this approval is a significant advancement as it provides an additional effective targeted therapy."

The European Commission's decision follows a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) on July 25 and is supported by results from the Phase II PHAROS trial. At the primary analysis cut-off on September 22, 2022, the trial achieved its primary endpoint, indicated by the objective response rate (ORR) assessed through independent radiology review (IRR). In the treatment-naïve group (n=59), the ORR was 75% (95% CI: 62, 85), including 15% complete responses (CRs) and 59% partial responses (PRs). Updated data with an additional 10-month follow-up revealed that 64% of patients sustained a response for a minimum of 12 months, with a median duration of response (mDOR) determined by IRR at 40 months (95% CI: 23.1, not estimable [NE]).

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of September 3, 2024, there are 59 investigational drugs for the BRAF targets, including 263 indications, 116 R&D institutions involved, with related clinical trials reaching 1710, and as many as 13678 patents.

Encorafenib is a small molecule drug that targets the protein BRAF. It is approved for the treatment of several types of cancers, including anaplastic thyroid cancer, non-small cell lung cancer, colorectal cancer, melanoma, brain cancer, and plasma cell myeloma refractory, among others. The drug is indicated for tumors with specific BRAF mutations and has shown efficacy in treating advanced and metastatic forms of these malignancies.

图形用户界面, 文本, 应用程序

描述已自动生成

Alnylam Unveils Phase 3 HELIOS-B Study Results of Vutrisiran in ATTR Cardiomyopathy at ESC Congress
Latest Hotspot
4 min read
Alnylam Unveils Phase 3 HELIOS-B Study Results of Vutrisiran in ATTR Cardiomyopathy at ESC Congress
4 September 2024
Alnylam Shares In-Depth Findings from Successful Phase 3 HELIOS-B Study of Vutrisiran in ATTR Amyloidosis Cardiomyopathy Patients at ESC Congress.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Sep 4
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Sep 4
4 September 2024
Sep 4th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Orgenesis Announces Positive Results from ORG-101 CAR-T Study in CD19+ Acute Lymphoblastic Leukemia
Latest Hotspot
4 min read
Orgenesis Announces Positive Results from ORG-101 CAR-T Study in CD19+ Acute Lymphoblastic Leukemia
4 September 2024
Orgenesis Reports Favorable Outcomes from a Practical Study on ORG-101 CAR-T Treatment in CD19+ Acute Lymphoblastic Leukemia Patients.
Read →
Johnson & Johnson Seeks Initial Approval for Nipocalimab in Treating Broad-Spectrum Myasthenia Gravis
Latest Hotspot
3 min read
Johnson & Johnson Seeks Initial Approval for Nipocalimab in Treating Broad-Spectrum Myasthenia Gravis
4 September 2024
Johnson & Johnson aims for initial approval of nipocalimab to treat a wide range of patients with antibody-positive generalized myasthenia gravis.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.